Celebrating the International Day of Women and Girls in Science

LifeArc celebrates this year's UN Day for Women and Girls in STEM.

Alzheimer’s drug lecanemab approved by US regulator

LifeArc’s Chief Scientific Officer Dr Dave Powell comments on news that lecanemab has received regulatory and safety approval from the FDA.

2022 wrapped – our highlights from a pivotal year

We’ve seen some exciting scientific progress, forged new partnerships and launched some new landmark initiatives.

MND Collaborative Partnership cautiously welcomes new Government funding

We cautiously welcome the Government's announcement on how their £50m commitment into MND research will be spent.

Repurposed flu medicine could help under 60s recover faster from COVID-19

Results of an international repurposing study show favipiravir could help with COVID-19.

LifeArc bolsters executive team with communications expertise

Welcome to Anna Tomlinson, who joins LifeArc as our first Chief Communications Officer.

LifeArc plays key role in discovery of new Alzheimer’s treatment

LifeArc played an important part in the discovery of lecanemab, an experimental drug that has shown some benefits for people with early Alzheimer’s disease.

LifeArc contributes to organic chemistry breakthrough

The findings reveal that seemingly impossible chemical reactions can be driven through a phenomenon called quantum tunnelling.

AbbVie acquires LifeArc portfolio company DJS Antibodies

AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS